What are the best Minecraft texture packs? These colorful and game-altering texture packs can make your world a new experience. Of course, Minecraft’s low-fi charm is part of the draw ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

The quintessential accessory of the 1990s, the fanny pack has made a stylish comeback. Today, this small yet mighty bag is a travel necessity for stashing essentials while keeping your hands free ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

Creators have even gone as far as creating whole packs of content, akin to the official Stuff Packs released by EA. If you like vampires – or vampire slayers, for that matter – then you might ...

Please verify your email address. Opening packs in TCG Card Shop Simulator is something that most players will do daily. Opening up packs and selling individual cards is a fantastic way to make ...

A common piece of advice when it comes to buying Sims 4 expansion packs is to wait until they're on sale. If you play on PC or Mac, you're in luck as online retailer CDKeys has dropped prices for ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...